Links:
Dr. John Cush @RheumNow( View Tweet )
Links:
Dr. John Cush @RheumNow( View Tweet )
A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures.
There were 15,123 RA patients (mean age 68.8 years) enrolled in Clinical Practice Research Datalink
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).
The manufacturer, Octapharma USA, received
Read Article
The ACR and the Vasculitis Foundation have published their evidence-based recommendations and expert guidance for the management of GCA and Takayasu arteritis. These recommendations address a variety of clinical questions and scenarios including diagnostic testing, imaging, treatments, and
Read Article
A single center analysis of systemic lupus erythematosus (SLE) patients found symptomatic osteonecrosis (ON) in nearly 10%.
Researchers analyzed data from 912 SLE patients admitted to the hospital (1981 to 2012). Of these 912 SLE patients, 97 had symptomatic ON with an overall
Read Article
Gradual withdrawal of glucocorticoids was successful among patients with systemic lupus erythematosus (SLE) after 2 years of clinically quiescent disease, without an increased likelihood of flares, Canadian researchers reported.
At 12 months, the flare rate among patients who had
Read Article
Links:
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Read Article
EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.
The
Read Article
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Read Article
EULAR 2021 opened with a grand debate to answer this essential question: should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?
Read Article
In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.
Importantly, treating people living with RMDs above the age of 70 -
Read Article
Eric Dein @ejdein1( View Tweet )
Aurelie Najm @AurelieRheumo( View Tweet )
Eric Dein @ejdein1( View Tweet )
k dao @KDAO2011( View Tweet )
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Eric Dein @ejdein1( View Tweet )
